Close

Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial

May 13, 2021 3:30 AM EDT

Second clinical molecule from Exscientia collaboration with Sumitomo Dainippon Pharma to begin Phase 1 trials in United States.

Clinical study of DSP-0038, a dual targeted 5-HT1A agonist and 5-HT2A antagonist to be assessed for treatment of Alzheimer’s disease psychosis.

OXFORD, England--(BUSINESS WIRE)-- Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) is pleased to acknowledge that Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan, Representative Director, President and CEO: Hiroshi Nomura) has announced that they will initiate a Phase 1 clinical study of DSP-0038 in the United States for the treatment of Alzheimer’s disease psychosis.

DSP-0038 is the third molecule created using Exscientia’s Artificial Intelligence (AI) technologies to enter clinical trials. The two earlier compounds are DSP-1181, announced in 2020 together with Sumitomo Dainippon Pharma to treat obsessive-compulsive disorder, and Exscientia’s immuno-oncology agent, EXS-21546, announced earlier this year.

Joint research between Exscientia and Sumitomo Dainippon Pharma designed DSP-0038 to be a single small molecule that exhibits high potency as an antagonist for the 5-HT2A receptor and agonist for the 5-HT1A receptor, whilst selectively avoiding similar receptors and unwanted targets, such as the dopamine D2 receptor. Selective dual targeting is a major challenge for conventional drug discovery, and psychiatric indications also require exceptional selectivity to avoid off-target effects. The successful design of DSP-0038 demonstrates opportunities to design selective molecules with dual activity.

DSP-0038 will be assessed for improved antipsychotic effects associated with Alzheimer’s disease psychosis, as well as improvements in behavioural and psychological symptoms of dementia which include agitation, aggression, anxiety, and depression.

Toru Kimura, Representative Director, Executive Vice President and Chief Scientific Officer of Sumitomo Dainippon Pharma, said: "We have been impressed by the outstanding productivity of Exscientia's AI technologies. The combination of Exscientia’s AI with our company’s deep experience in monoamine GPCR drug discovery has now led to two molecules reaching our clinical pipeline from this collaboration.”

Andrew Hopkins, CEO of Exscientia, said: "This is further validation that our AI platform can turn complex biological challenges into high-quality clinical candidates quickly. To have what we believe to be the world’s first three clinical molecules created using AI arising from our own platform – two with Sumitomo Dainippon Pharma - is a wonderful achievement. We hope that through the creation of DSP-0038 improved treatments for Alzheimer’s disease psychosis will be realized."

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed two drugs that are in Phase 1 human clinical trials.

Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.

Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.

About Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma defines its corporate mission as "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." By pouring all our efforts into the research and development of new drugs, we aim to realize our corporate mission and provide innovative and effective pharmaceutical

solutions to people not only in Japan but also around the world. Sumitomo Dainippon Pharma's goal is to create innovative pharmaceutical products in the focus research areas of Psychiatry & Neurology, Oncology and Regenerative Medicine/Cell Therapy. For further details, visit https://www.ds-pharma.com.

Enquiries:
Edelman
Anitra Sprauten
P: +44 (0)7896 859386
[email protected]

Stephanie Crisp
P: +44 (0)7583 003417
[email protected]

For Exscientia
Mark Swindells: [email protected]

Source: Exscientia Ltd.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Business Wire, Press Releases

Related Entities

Twitter, Nomura